Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
Clinical trial NCT05308264 · RECRUITING
Trial details
- NCT number
- NCT05308264
- Sponsor
- Rigel Pharmaceuticals
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-12
- Primary completion
- 2026-08-01
- Enrollment
- 86
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.